Wall Street Zen upgraded shares of Evoke Pharma (NASDAQ:EVOK – Free Report) from a sell rating to a hold rating in a research report report published on Sunday.
Evoke Pharma Price Performance
Shares of Evoke Pharma stock opened at $5.18 on Friday. Evoke Pharma has a 1 year low of $1.94 and a 1 year high of $12.32. The firm’s 50-day moving average is $4.94 and its two-hundred day moving average is $3.71. The stock has a market cap of $8.08 million, a price-to-earnings ratio of -2.02 and a beta of -0.13.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last issued its earnings results on Thursday, August 14th. The specialty pharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.32). Evoke Pharma had a negative return on equity of 99.48% and a negative net margin of 42.07%.The business had revenue of $3.75 million for the quarter, compared to the consensus estimate of $3.80 million.
About Evoke Pharma
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Featured Stories
- Five stocks we like better than Evoke Pharma
- What is the Hang Seng index?
- Is Qualcomm Tesla’s Next Rival in Autonomous Driving?
- Trading Halts Explained
- 3 Under-the-Radar Biotechs Under $5 That Could Soar 200%
- What is a buyback in stocks? A comprehensive guide for investors
- The Quiet Before the Catalyst: Vertical Aerospace’s Next Move
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
